





Sayre Therapeutics is a dynamic and nimble healthcare company with an accelerated growth-curve via its unique business model. We offer a high value platform to global partners looking to introduce their healthcare assets in the South Asian markets and in turn opening up a plethora of options, hitherto unavailable to patients.

Our key pillars help us deliver meaningful business opportunities to partners and offer best-in-class medicines and devices to the patient population in South Asia.

End-to-end integrated solutions across drugs, devices and diagnostics

- Key opinion leaders (KOLs) and market shapers across oncology and immunology therapy areas
- Highly efficient distribution and supply-chain platform
- Futuristic disease management for stronger patient profiling with the personalized treatment options

Bringing global innovations to South Asian markets with high unmet need

Sayre focuses on the South Asian markets (SAARC) of Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka, where given the high disease burden, Sayre will contribute to improving the quality of care for cancers and autoimmune conditions, by sustained engagement with physicians and providing affordable medicines to patients. The cancer incidence in SAARC is roughly 10 % of the world's cases with ~1.5 MM cancer cases diagnosed every year. Yet, the burden of cancer deaths compared to the incidence is ~70% and compares poorly to the 60% for the world, as patients in SAARC countries present in advanced stages of the disease where the prognosis is poor.

The prevalence of autoimmune diseases in SAARC countries range from 13-40 MM cases. Autoimmune problems have a strong genetic predisposition but triggers may include excessive sun, infections, drugs, or other conditions — such as pregnancy — that stress the body and the incidence of autoimmune disorders is on the rise in South Asia.



We focus on bringing novel medicines, drug-delivery devices, molecular diagnostics and diagnostic imaging agents to medical oncologists, surgical oncologists, radiation oncologists, interventional radiologists, rheumatologists and immuno-dermatologists.

In-licensing healthcare products across the continuum of Oncology and Immunology

Drugs

Sayre promotes novel and/or differentiated medicines in-licensed from global pharmaceutical and biotech companies. Sayre focuses on niche products and orphan medications, which will include but will not be limited to small molecules, recombinant proteins and monoclonal antibodies (mAbs) in Oncology and Immunology.

Novel Drug Delivery Devices


In delivering therapeutic agents with improved efficacy and minimum side effects, novel drug delivery systems (NDDS) have created a paradigm shift in the pharmaceutical market. The current market for NDDS in India is on an upsurge owing to its manifold advantages such as safety, high efficacy, improved pharmacokinetics, decreased dosing frequency, reduced side effects and patient compliance. Sayre promotes devices such as spray systems, micro-needles for transdermal drug and vaccine delivery, depot systems and needle-free auto-injectors.

Molecular Diagnostics

Newer, automated technologies have transformed the way physicians detect and diagnose cancers and genetic diseases at an early stage. This has also paved the way for personalized medicine, which can identify the predisposition of a patient, disease based on genetic variants, and target therapy at the right time. We collaborate with diagnostic labs and partners to provide access to innovative molecular and companion diagnostic products aimed at transforming patient care.

Commercializing global healthcare assets whilst navigating the clinical and regulatory requirements of South Asian markets

We are Asia's only super-specialized distribution and commercialization platform for Oncology and Immunology assets. Our business model encompasses Global access/early access programs, Named Patient programs and securing product registrations for exclusive commercial distribution in South Asia. We aspire to be the partner of choice for oncology and immunology companies having limited to no commercial footprint in South Asia.



Assuring high levels of quality and integrity


We are committed to doing business in an ethical and socially responsible manner. We comply with all necessary steps as per Indian regulatory authorities (CDSCO/DCGI & ICMR) guidelines/standards from inception of project discussion to registration of the products, providing a seamless introduction of globally approved products in India and South Asia. We work closely with highly experienced regulatory firms to utilize their expertise in regulatory strategy development, evaluation of data gap analysis, regulatory writing, dossier preparation and submission, project management and post-approval documents maintenance.



Facilitating advanced
treatment options to
patients and physicians



Committed to making treatment more
convenient to patients and physicians



About Sayre Therapeutics

Sayre has been identified as a high potential unique healthcare company and funded by two of the largest global healthcare venture capital firms.

Sayre is a first-of-a-kind integrated solution platform across novel and differentiated high-value drugs, drug-delivery devices and molecular diagnostics.

Sayre combines high-science knowledge in identifying products serving high unmet needs to targeted selling toward the super-specialties of Oncology & Immunology.

Sayre successfully opens up the South Asian markets for companies globally to commercialize their products.

Sayre employs a senior team of doctors, pharmacists and marketers.



Sayre Therapeutics Pvt. Ltd., First Floor, No.2 AVS Compound
80 Feet Main Road, 4th Block, Koramangala, Bangalore – 560 034
info@sayretherapeutics.com, www.sayretherapeutics.com